AdvanDx Secures $2.2M for In Vitro Diagnotic Tests
October 31, 2012
Share:
AdvanDx, a developer of in vitro diagnostic tests for infectious diseases, has raised $2.2 million out of a target $6.1 million offering. Previously, AdvanDx raked in a healthy $34 million over three rounds of financing from investors including BioMerieux, LD Pensions and Scandinavian Life Science Venture.